Stocktoria
Quoin Pharmaceuticals, Ltd. QNRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1989-11-01
Quoin Pharmaceuticals, Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| R&D expense | $9.8M | $3.6M | $3.3M | $2.7M | $1.6M |
| SG&A expense | $6.5M | $5.9M | $6.1M | $6.6M | $4.5M |
| Interest expense | — | — | — | — | $1.1M |
| Net income | -$15.8M | -$9.0M | -$8.7M | -$9.4M | -$21.5M |
| EPS (diluted) | — | — | — | — | $-0.01 |
| Operating cash flow | -$13.5M | -$7.9M | -$7.9M | -$8.5M | -$5.7M |
| Cash & equivalents | $3.8M | $3.6M | $2.4M | $2.9M | $7.5M |
| Total assets | $20.4M | $15.7M | $12.2M | $14.5M | $9.4M |
| Total liabilities | $7.3M | $6.5M | $6.5M | $7.1M | $8.7M |
| Shareholders' equity | $13.1M | $9.2M | $5.7M | $7.4M | $657,032 |
Source: SEC EDGAR filings · CIK 0001671502 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.